A program to present naloxone overdose-antidote kits and coaching to front-line officers. Funding for capsule disposal packing containers in pharmacies, clinics and police stations throughout North Carolina. A radio marketing campaign in Connecticut warning of the risks of opioid abuse. A brand new medication to deal with opioid-induced constipation.
The cash behind these efforts to fight the opioid epidemic and its unintended effects comes from a maybe unlikely sponsor: Purdue Pharma, the corporate that makes the top-selling opioid, OxyContin.
After years of aggressively selling OxyContin as a secure and efficient strategy to fight ache, the corporate is — equally aggressively — recasting itself as a basic participant within the response to a disaster that many specialists say it helped to create. Such efforts come amid tons of of lawsuits claiming that Purdue fueled the opioid epidemic by deceptively advertising and marketing OxyContin, in addition to new authorities efforts to control opioids.
In February, Purdue introduced that it might cease selling its opioid medicine to physicians. At the identical time, Purdue is seeking to accomplice with different firms and increase its portfolio into areas akin to oncology and sleep medication. OxyContin accounted for greater than 94 p.c of Purdue’s gross sales in 2012 and was nonetheless over 82 p.c as of final 12 months, in keeping with Symphony Health.
While affected person teams and communities have been fast to simply accept cash for applications they may in any other case not afford, households who’ve misplaced family members to opioids aren’t simply placated.
When Sue Kruczek heard the Purdue-sponsored radio advert on her native station, warning of the risks of opioid habit, she was so appalled that she stated she “almost had to pull over.”
“It’s sickening. It makes me feel sick. I hold Purdue personally responsible for this epidemic,” stated Kruczek, who misplaced her son Nick to an opioid overdose in 2013, only a week shy of his 21st birthday. “It’s blood money at this point.”
Kruczek stated she was additionally unimpressed by the full-page ads Purdue positioned in main newspapers in December, touting its “abuse-deterrent” OxyContin formulation and help for the Centers for Disease Control and Prevention pointers for secure prescribing.
Greg Williams, government vice chairman of Facing Addiction, a nonprofit group that advocates for individuals combating habit, famous that the adverts had been printed simply months after a coalition of 41 states’ attorneys common subpoenaed records from main opioid producers, together with Purdue. “The timing of this recent blitz is not an accident — they were quiet for a long time,” he stated of the adverts and donations, calling them a tactic to keep away from paying extra later. “They’re spending millions of dollars to do this when they owe billions,” he stated.
Purdue stated it’s incorrect in charge the corporate for the opioid disaster, which resulted in 42,000 overdose deaths in 2016. The Council of Economic Advisers estimated that the disaster price $504 billion in 2015, or 2.Eight p.c of GDP.
Email Sign-Up
Subscribe to KHN’s free Morning Briefing.
“Pointing fingers isn’t a way to get the resolution we need,” Robert Josephson, a spokesman for Purdue, stated in an interview. “Pointing to one company and one product that never constituted more than 3.6 percent of total prescriptions really misses the mark.” The commercials all finish with the phrase: “We want everyone engaged to know you have a partner in Purdue Pharma. This is our fight, too.”
Some applications which have benefited from Purdue’s donations say they had been unaware that the drugmaker had supplied the funding — although within the midst of a disaster they had been nonetheless grateful.
As a part of Purdue’s partnership with the National Sheriffs’ Association, the sheriff’s division in rural Wood County, Ohio, acquired about 60 doses of naloxone for officers to hold. So far, the division has used about seven doses to revive individuals experiencing an overdose.
Sheriff Mark Wasylyshyn stated that when he acquired the kits he was not conscious that Purdue had supplied the funds. But, he stated, it might not have affected his resolution to simply accept them. “I think whoever wants to do it, it’s wonderful,” he stated. “If they wouldn’t have done it, I wouldn’t have had it to save those seven lives.”
Fred Wells Brason II, president and CEO of Project Lazarus in North Carolina, which partnered with Purdue to put in capsule disposal packing containers throughout the state, stated the group had acquired little pushback for accepting the donation. The drug firms “are not going to go away. We need them, and patients need them. We just want to make sure prescribing is safe and responsible,” he stated.
OxyContin gross sales have been dropping lately, from $2.Eight billion in 2012 to $1.7 billion in 2017, partially due to competitors from generics. Unlike different opioid producers akin to Johnson & Johnson, which makes tons of of merchandise, Purdue is understood nearly solely for its opioid medicine.
That is partly why it’s soliciting enterprise partnerships to range its portfolio. But one of many first of the brand new merchandise feels to some like an affront: Acquired by means of a partnership with Japanese company Shionogi Inc. and permitted final 12 months, Symproic is a capsule to deal with opioid-induced constipation — a standard illness of individuals taking the ache meds. It prices about $350 per thirty days.
Purdue’s current promise to chop half of its gross sales employees and cease advertising and marketing OxyContin to physicians altogether is unlikely to have a lot of an affect, particularly since there are already generic variations of the drug, stated Andrew Kolodny, co-director of opioid coverage analysis on the Heller School for Social Policy and Management at Brandeis University.
“Once drug companies have generic competition, they often stop promoting anyway,” he stated, including that OxyContin remains to be being marketed aggressively in different nations by means of Purdue’s worldwide arm, known as Mundipharma. Although OxyContin remains to be protected by a Purdue patent, it’s out there in a number of generic equal types, offered by generic drug firms with Purdue’s permission.
The firm’s strategy is nothing new, stated Mike Moore, a former legal professional common of Mississippi who’s presently consulting on a number of main circumstances in opposition to Purdue. “They have had a history of tiny half-steps every time someone begins looking at them,” stated Moore. In 2002 for instance, Moore recalled, Purdue gave Florida $2 million for schooling and prevention applications to fight opioid abuse. “That’s like pennies in a coffee can. It doesn’t do anything,” stated Moore.
Any world settlement with Purdue and different opioid producers would must be not less than $100 billion to noticeably handle the opioid disaster, Moore stated.
Even as Purdue has in the reduction of its gross sales power and has been spending on hurt discount, it continues to advertise prescribing of opioids.
From 2012 to 2017, for instance, Purdue gave $four.15 million in funding to affected person advocacy organizations societies such because the Academy of Integrative Pain Management and the American Academy of Pain Medicine, a current U.S. Senate investigation found. Many of the teams, in flip, issued statements and pointers that minimized the chance of long-term use of opioids to deal with power ache, in keeping with the Senate’s report.
In 2007, Purdue pleaded guilty in federal court to deceptive docs and sufferers about OxyContin’s danger of habit and potential for abuse, and agreed to pay $600 million in fines. The interval beneath investigation, nonetheless, led to mid-2001. Since then, Josephson stated, Purdue has realized from its previous errors and has a superb monitor report. “We as a company have been addressing prescription drug abuse for 15 years,” stated Josephson.
Thus far, critics word, Purdue’s efforts haven’t included strategies that might considerably cut back or restrict gross sales of OxyContin, the corporate’s blockbuster high-dose opioid drug. In statements about opioid misuse, for instance, Purdue avoids the usage of the time period “addiction” and as a substitute focuses on “abuse” of medication.
“There’s a real sense that they’re saying, ‘We’re not the drivers of the problem, the addicts are the drivers of the problem. We’re going to try to help, but really it’s the addicts and the people trafficking in this illegally that are the problem,’” stated W. Timothy Coombs, a professor of disaster communications at Texas A&M University.
Said Adriane Fugh-Berman, who research pharmaceutical advertising and marketing practices on the Georgetown University Medical Center: “If they were really sincere, they would be looking for ways to sell fewer opioids. We’re not seeing that.”
KHN’s protection of prescription drug improvement, prices and pricing is supported by the Laura and John Arnold Foundation.
Jenny Gold: [email protected]”>[email protected], @JennyAGold
Related Topics Cost and Quality Courts Health Industry Mental Health Pharmaceuticals Public Health Opioids Substance Abuse src=”http://platform.twitter.com/widgets.js” charset=”utf-Eight”>
